Product Categories

Dasatinib (BMS-354825)

Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.5 nM and 79 nM, respectively.

Catalog No.S1021
5 5 10 Reviews 26 Product Citations
Price Stock Quantity  
USD 147 In stock
USD 370 In stock
Contact Us Bulk Inquiry Add to Wishlist

Free Overnight Delivery on all orders over $ 500.

Order now and get it on

Tel: +1-832-582-8158[email protected]

Dasatinib (BMS-354825) Chemical Structure
Molecular Weight: 488.01

Validation & Quality Control

Customer Reviews(10)

Quality Control & MSDS

Related Compound Libraries

Dasatinib (BMS-354825) is available in the following compound libraries:

Cambridge Cancer Compound Library(96-well) Chemical Library (96-well) Chemotherapeutic Agent Library (96-well) FDA Approved Drug Library (96-well) Inhibitor Library (96-well) Kinase Inhibitor Library (96-well) Stem Cell Small Molecule Compound Library (96-well) Tyrosine Kinase Inhibitor Library (96-Well)

Product Information

  • Compare Src Inhibitors
    Compare Src Inhibitors
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity Protocol Chemical Information Customer Reviews Product Citations Tech Support & FAQs

Biological Activity

Description Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.5 nM and 79 nM, respectively.
Targets Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

 79 nM/37 nM [2]
In vitro Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
Clinical Trials Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

Cell Assay:

[1]

Cell lines Ba/F3 cell lines
Concentrations ~32 nM
Incubation Time 72 hours
Method

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

Animal Study:

[3]

Animal Models EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
Formulation DMSO
Dosages 30 mg/kg
Administration Administered via i.p.
1

References

Chemical Information

Download Dasatinib (BMS-354825) SDF
Molecular Weight (MW) 488.01
Formula

C22H26ClN7O2S
CAS No. 302962-49-8, 854001-07-3 (HCl)
Synonyms Sprycel
Solubility (25°C)
  • DMSO 98 mg/mL
  • Water <1 mg/mL
  • Ethanol <1 mg/mL
Storage 2 years -20°CPowder
2 weeks4°Cin DMSO
6 months-80°Cin DMSO
Chemical Name N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Molarity Calculator Dilution Calculator Molecular Weight Calculator

Research Area

Customer Reviews (10)


Click to enlarge 		Rating
Source Invest New Drugs , 2010, 30(1), 417-422. Dasatinib (BMS-354825) purchased from Selleck
Method Western blot
Cell Lines p53wild-type(EHEB, JVM-2) cell lines, p53mutated(MEC-2, BJAB) cell lines
Concentrations 10 μM
Incubation Time 24 h
Results "Upon exposure to Dasatinib, a decrease of phosphorylated proteins was confirmed by Western blot analys is in all cell lines investigated without significant differences between p53wild-type and p53mutated cell lines.

Click to enlarge 		Rating
Source Biochem Pharmacol , 2011, 82(10), 1457-1466. Dasatinib (BMS-354825) purchased from Selleck
Method Evaluation of differentiation
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 5 μM
Incubation Time
Results In a first series of experiments, we assessed four signs of morphological differentiation, May-Gruenwald-Giemsa staining of MOLM-13 cells demonstrated that dasatinib induced a dose-dependent decrease in cytoplasmic basophilia and in the nucleo-cytoplasmic ratio. Dasatinib also led to the appearance of dented nuclei and cytoplasmic granulation( Fig.A and B).In HL-60 cells,dasatinib(5 μM) once more exhibited the highest differentiation-inducing capacity. Thus dasatinib diminished basophilia of the cytoplasm concomitantly with the nucleo-cytoplasmic ratio, and induced the appearance of nuclear lobulation and cytoplasmic granules(Fig. G). Next, we determined the degree of CD11b expression, a marker indicating myeloid differentiation, in TKI-treated MOLM-13 dasatinib exhibited the most pronounced capacity to increase CD11b surface expression( Fig. C and D).To corroborate the TKI-driven differentiation, we quantified the enzymatic activity of alkaline phosphatase by means of the NBT-reduction assay after an incubation period of 6 days in MOLM-13 cells.,Once again, the NBT-reductive activity was highest in cells treated with dasatinib, which was as active as the positive control, ATRA( Fig. E and F)

Click to enlarge 		Rating
Source Invest New Drugs , 2010, 30(1), 417-422. Dasatinib (BMS-354825) purchased from Selleck
Method Assessment of cell viability
Cell Lines leukemic cells
Concentrations 10 μM
Incubation Time 24/48 h
Results Dasatinib dose-dependently reduced cell viability in all leukemic cell lines, with variable efficacy irrespect ively of the p53 status. In particular, when used at 10 μM, Dasatinib induced a progressive decrease of the total number of viable cells ranging from approximately 30% (JVM-2 and MEC-2) to 50% (EHEB and BJAB) after 48 h of treat ment (Fig.a). In order to investigate whet her the decreased leukemic cell viability was mainly due to either cytotoxic or cytostatic activity, we have analyzed the effects of Dasatinib on apoptosis,As shown in Fig. b, exposure to Dasatinib induced a significant (p < 0.05) increase of apoptosis in all leukemic cell lines, as evaluated by Annexin-V/PI staining at 48 h of treatment.

Click to enlarge 		Rating
Source Invest New Drugs , 2010, 30(1), 417-422. Dasatinib (BMS-354825) purchased from Selleck
Method phospho-kinase array analysis
Cell Lines EHEB (p53wt) cell lines, BJAB (p53mut) B cell lines
Concentrations
Incubation Time 24 h
Results As shown in Fig. a , the most evident effects of Dasatinib in both cell models were represented by a significant down-regulation of the phosphorylation levels of p38 MAPK, ERK1/2 and CREB. In addition, densitometric analysis of the phospho-kinase array demonstrated that Dasatinib also inhibited the phosphorylation levels of several STAT family members (STAT1, STAT2, STAT3, STAT5a/b and STAT6), the most evident effect in both p53 wild-type (EHEB) and p53 mutated (BJAB) cell lines being on STAT2, STAT3 and STAT6 (Fig. b)

Click to enlarge 		Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib (BMS-354825) purchased from Selleck
Method Assessment of cell viability and apoptosis
Cell Lines B-CLL patient leukemic cells
Concentrations 2-10 μM
Incubation Time 48 h
Results The Dasatinib+Nutlin-3 combination promotes synergistic cytotoxicity in primary CLL cells as well as in p53 wild-type and p53 deleted/ mutated leukemic cell lines.

Click to enlarge 		Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib (BMS-354825) purchased from Selleck
Method Western blot
Cell Lines Leukemic cell lines
Concentrations 10 μM
Incubation Time 24 h
Results Dasatinib marginally affected both the basal levels of p53 and the accumulation of p53 induced by Nutlin-3 in the p53 wild -type cells (Fig. A).Interestingly, however, levels of both MDM2 and p21 proteins, 2 of the best characterized transcriptional targets of p53, weres significantly (P < 0.05) decreased in cells treated with Dasatinib+ Nutlin-3 with respect to cells treated with Nutlin-3 alone (Fig. B).

Click to enlarge 		Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib (BMS-354825) purchased from Selleck
Method Phospho-kinase array analysis
Cell Lines EHEB cell lines/BJAB cell lines
Concentrations 10 μM
Incubation Time 16 h
Results Although Nutlin-3 had no effects on these pathways, Dasatinib alone as well as Dasatinib+Nutlin-3 markedly inhibited the basal phosphorylation of ERK1/2, p38/MAPK, and Akt . Of interest, the combination of Dasatinib+Nutlin-3 selectively enhanced (P < 0.05) the inhibition of Akt phosphorylation with respect to Dasatinib alone, as validated by Western blot analysis.

Click to enlarge 		Rating
Source Dr Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib (BMS-354825) purchased from Selleck
Method Cell vability assays
Cell Lines A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2, HepG2 cell lines
Concentrations 0.001-1000 nM
Incubation Time 24/96 h
Results

Click to enlarge 		Rating
Source Biochem Pharmacol , 2011, 82(10), 1457-1466. Dasatinib (BMS-354825) purchased from Selleck
Method MTT assay
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 1-15 μM
Incubation Time 24-72 h
Results Dasatinib and other TKI decreased the viability of the two myeloid cell lines in a dose- and time-dependent manner. Nevertheless, the anti-leukemic efficacy of Dasatinib and other TKI varied considerably in both cell lines.

Click to enlarge 		Rating
Source Cell Res, 2011, 21, 1080-1087. Dasatinib (BMS-354825) purchased from Selleck
Method Microangiography
Cell Lines embryos
Concentrations 30 μM
Incubation Time
Results MEK1/2 may cooperate with VEGFR to regulate blood vessel lumen diameter. We examined this hypothesis by combining VEGFR inhibitor Sunitinib and MEK1/2 inhibitor U0126. Indeed, U0126 (10 µM) combined with Sunitinib (20 µM) resulted in a reduction of vessel lumen size (Figure F), whereas individually they did not. Combined treatment of another MAP kinase signaling pathway inhibitor Dasatinib (20 µM) with Sunitinib (20 µM) produced a similar phenotype as PP1, whereas each individual inhibitor did not result in any vessel shrinkage even at much higher concentrations ( Figure C).Since there are three major VEGF receptors, it is desirable to determine which receptor is involved in combinatory action with MEK1/2. To address this issue, additional highly selective VEGFR inhibitors PTK787 and ZM323881 were tested. Both of these inhibitors (PTK787 or ZM323881), when individually combined with Dasatinib or U0126, induced a reduction of vessel lumen size (Figure D, E, G, and H).

Product Citations (26)

  • Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. [Gibbs KD Jr, et al. Cell Stem Cell 2012;10(2):210-7]

    PubMed: 22305570

  • Dasatinib inhibits proinflammatory functions of mature human neutrophils. [Futosi K, et al. Blood 2012;119(21):4981-91]

    PubMed: 22411867

  • Combinatory action of VEGFR2 and MAP kinase pathways maintains endothelial-cell integrity. [Zhong H, et al. Cell Res 2011;21(7), 1080-1087]

    PubMed: 21423276

  • STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. [Sen B, et al. Clin Cancer Res 2012;18(1):127-39]

    PubMed: 22090359

  • Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53wild-type and p53mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. [Zauli G, et al. Clin Cancer Res 2011;17(4), 762-770]

    PubMed: 21106726

  • Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. [Lainey E, et al. Oncogene 2012;ahead of print]

    PubMed: 23085751

  • Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion. [Mineo M, et al. Angiogenesis 2012;15(1):33-45]

    PubMed: 22203239

  • Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive. [Gavrilovskaya IN, et al. J Virol 2012;86(16):8765-72]

    PubMed: 22696643

  • VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. [Gorbunova EE, et al. J Virol 2011;85(5), 2296-2303]

    PubMed: 21177802

  • MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi‐kinase inhibitor Sorafenib with respect to Dasatinib. [Secchiero P, et al. Br J Haematol 2012;157(4):510-4]

    PubMed: 22313359

  • Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. [Deep G, et al. Cancer Prev Res (Phila). 2011;4(8):1222-32]

    PubMed: 21546539

  • Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. [Lainey E, et al. Biochem Pharmacol 2011;82(10), 1457-1466]

    PubMed: 21664897

  • Cyclophilin D Extramitochondrial Signaling Controls Cell Cycle Progression and Chemokine-Directed Cell Motility. [Tavecchio M, et al. J Biol Chem 2013;ahead of print]

    PubMed: 23303179

  • Role of increased guanosine triphosphate cyclohydrolase-1 expression and tetrahydrobiopterin levels upon T cell activation. [Chen W, et al. J Biol Chem 2011;286(16):13846-51]

    PubMed: 21343293

  • Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. [Okabe S, et al. Stem Cells Dev 2012;21(16):2939-48]

    PubMed: 22642671

  • Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers. [Kruewel T, et al. PLoS ONE 2010;5(11), e14143]

    PubMed: 21152443

  • The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors. [Schwarzbich MA, et al. Cancer Immunol Immunother 2012;61(2), 193-202]

    PubMed: 21874302

  • Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells. [Lipka DB, et al. PLoS One 2012;7(7):e40853]

    PubMed: 22815843

  • p38α MAP Kinase Dimers with Swapped Activation Segments and a Novel Catalytic Loop Conformation. [Rothweiler U, et al. J Mol Biol 2011;411(2):474-85]

    PubMed: 21699901

  • Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: Evidence for a noninvasive treatment of high-grade dysplasia. [Inge LJ, et al. J Thorac Cardiovasc Surg 2013;145(2), 531-538]

    PubMed: 23142123

  • Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells. [Bosco R, et al. Invest New Drugs 2012;30(1), 417-422]

    PubMed: 20953816

  • Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. [Wasag B, et al. Exp Hematol 2011;39(8):859-65.e2]

    PubMed: 21689725

  • Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers. [Cheung HW, et al. Cancer Discov 2011;1(7):608-25]

    PubMed: 22586683

  • Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study. [Uchiyama T, et al. Hematol Oncol 2012;ahead of print]

    PubMed: 23108877

  • Development and Validation of a High-Throughput Intrinsic ATPase Activity Assay for the Discovery of MEKK2 Inhibitors. [Ahmad S, et al. J Biomol Screen 2012;ahead of print]

    PubMed: 23134735

  • High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal … [Marek Dziadosz, et al. Journal of Liquid Chromatography & Related Technologies 2012;35, 17]

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions
Tel: +1-832-582-8158 Ext:3Monday–Friday 9:00 AM–5:00 PM (Central Time)

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Inhibitors

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a Src inhibitor for c-Src and v-Abl with IC50 of 2.7 nM and 30 nM, respectively.

  • Dovitinib (TKI-258)

    Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively.

  • Motesanib Diphosphate (AMG-706)

    Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3, PDGFR, c-Kit and Ret with IC50 of 2 nM/3 nM/6 nM, 84 nM, 8 nM and 59 nM, respectively.

  • Masitinib (AB1010)

    Masitinib is a novel tyrosine kinases inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, resectively.

  • Vatalanib 2HCl (PTK787)

    Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR, Flt-1 and c-Kit with IC50 of 37 nM, 77 nM and 730 nM, respectively.

  • Danusertib (PHA-739358)

    Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively.

  • AT9283

    AT9283 is a potent pan-Aurora inhibitor for Aurora A, Aurora B, JAK3, JAK2 and Abl with IC50 of 3 nM, 3 nM, 1.1 nM, 1.2 nM and 4 nM, respectively.

  • Tivozanib (AV-951)

    AV-951 (Tivozanib, KRN-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 0.21 nM/0.16 nM/0.24 nM and also inhibits PDGFR and c-Kit with IC50 of 1.72 nM and 1.63 nM, respectively.

  • OSI-930

    OSI-930 is a potent inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck with IC50 of 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM, respectively.

  • Amuvatinib (MP-470)

    MP-470 (Amuvatinib) is a potent and multi-targeted inhibitor of c-KitD816H, PDGFαV561D and Flt3D835Y with IC50 of 10 nM, 40 nM and 81 nM, respectively.

RTKs and Angiogenesis Related Products

> Download

Recently Viewed Items

Tags: buy Dasatinib (BMS-354825) | Dasatinib (BMS-354825) ic50 | Dasatinib (BMS-354825) price | Dasatinib (BMS-354825) cost | Dasatinib (BMS-354825) solubility dmso | Dasatinib (BMS-354825) purchase | Dasatinib (BMS-354825) manufacturer | Dasatinib (BMS-354825) research buy | Dasatinib (BMS-354825) order | Dasatinib (BMS-354825) mouse | Dasatinib (BMS-354825) chemical structure | Dasatinib (BMS-354825) mw | Dasatinib (BMS-354825) molecular weight | Dasatinib (BMS-354825) datasheet | Dasatinib (BMS-354825) supplier | Dasatinib (BMS-354825) in vitro | Dasatinib (BMS-354825) cell line | Dasatinib (BMS-354825) concentration | Dasatinib (BMS-354825) nmr
Contact Us